Pfizer’s CEO Albert Bourla has revamped sales tactics, leading to a 31% rise in U.S. sales of Nurtec migraine medication, reports The Wall Street Journal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback